Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ferric Derisomaltose→

Ferric Derisomaltose Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
~150000 g/mol
Drug class
Intravenous ferric iron–carbohydrate complexparenteral iron replacement agent
Mechanism of action
A stable iron(III)-hydroxide complex with derisomaltose carbohydrate. After intravenous administration, iron is taken up by reticuloendothelial cells and released for transferrin binding, haemoglobin synthesis and replenishment of iron stores; it is not a simple iron salt.
Indications / reported uses
  • Treatment of iron-deficiency anaemia in adults who have intolerance to oral iron or have had an unsatisfactory response to oral iron
  • Use in adults with non-dialysis-dependent chronic kidney disease or other specified causes of iron deficiency according to the product label

Sources: US DailyMed — MONOFERRIC (ferric derisomaltose) · EMA EPAR — Monofer · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Ferric Derisomaltose Environmental Risk Assessment (ERA) (the Ferric Derisomaltose ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.